Condition

Lymphoma, B-Cell clinical trials and research

• 19Clinical trials
• 8Countries

Newest Lymphoma, B-Cell clinical trials

All recruiting trials (19)

• UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas

  A phase 1/2 trial tests UB-VV400 plus rapamycin in adults with relapsed or refractory B-cell lymphomas to see if it is safe and shows anti-tumor activity.

  Recruiting at 2 sites Phase 1/2 Umoja Biopharma · Irvine, California and 1 other locations · NCT07735533

• Ronde-cel versus standard CD19 CAR T‑cell therapy for relapsed or refractory large B‑cell lymphoma

  This test sees if ronde-cel, a CAR T therapy that targets both CD19 and CD20, works better than currently used CD19 CAR T therapies for adults whose large B‑cell lymphoma returned or did not respond after first‑line treatment.

  Recruiting at 41 sites Phase 3 Lyell Immunopharma, Inc. · Gilbert, Arizona and 43 other locations · NCT07188558

• Evaluating treatment options for posttransplant lymphoproliferative disorder

  This study is testing a combination of rituximab and chemotherapy for patients with high-risk posttransplant lymphoproliferative disorder to see if it helps them better than just using rituximab alone.

  Recruiting Phase 2 Columbia University · Stanford, California and 1 other locations · NCT06954805

• CAR-T cell therapy for children with relapsed leukemia or lymphoma

  This study is testing a new CAR-T cell therapy to see if it can help children with relapsed leukemia or lymphoma feel better and improve their chances of recovery.

  Recruiting Hong Kong Children's Hospital · Hong Kong · NCT06866873

• Using CD30 CAR-T therapy for treating relapsed lymphoma

  This study is testing a new treatment using modified T cells to see if it can help people with relapsed lymphoma that has the CD30 marker.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shangxi · NCT06850285

• Testing BTM-3566 for patients with relapsed or refractory mature B cell lymphomas

  This study is testing a new drug called BTM-3566 to see if it can help adults with relapsed or hard-to-treat mature B cell lymphomas feel better and improve their condition.

  Recruiting at 2 sites Phase 1 Bantam Pharmaceuticals · Charlotte, North Carolina and 1 other locations · NCT06792734

• Optimizing therapy for newly diagnosed diffuse large B-cell lymphoma using ctDNA

  This study is testing if measuring tumor DNA in the blood during treatment can help people with newly diagnosed diffuse large B-cell lymphoma get less chemotherapy if their cancer shows no signs of activity.

  Recruiting Columbia University · New York, New York · NCT06693830

• Using Axicabtagene Ciloleucel to improve outcomes after initial treatment for high-risk Large B-cell Lymphoma

  This study is testing if a one-time treatment with Axicabtagene Ciloleucel can help people with high-risk Large B-cell Lymphoma do better after their initial therapy.

  Recruiting Phase 4 Zhengzhou University · Zhengzhou, Henan · NCT06609304

• Testing UB-VV111 with and without Rapamycin for B-cell cancers

  This study is testing a new treatment called UB-VV111, with and without another drug called rapamycin, to see if it can help people with certain types of B-cell cancers that haven't responded to other treatments.

  Recruiting at 9 sites Phase 1 Umoja Biopharma · Duarte, California and 8 other locations · NCT06528301

• Early palliative care for patients with multiple myeloma and aggressive lymphoma

  This study is testing if early palliative care can improve the quality of life and comfort for people with multiple myeloma and aggressive lymphoma while they receive their usual cancer treatment.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT06485076

• Early heart function check after CAR-T treatment

  We will test whether people treated with CAR‑T cells for blood cancers have early changes in heart function by doing an ultrasound and blood tests 3–5 days after infusion.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT06350994

• Observational study on predicting treatment response in diffuse large B-cell lymphoma

  This study is trying to see if using machine learning can help doctors predict which patients with diffuse large B-cell lymphoma might not respond to treatment, so they can provide better care.

  Recruiting Grand Hôpital de Charleroi · Charleroi, Hainaut · NCT06241729

• Treatment of B-cell malignancies with ALETA-001

  This study is testing a new treatment called ALETA-001 to see if it can help people with relapsed non-Hodgkin lymphoma who didn't respond well to previous therapies.

  Recruiting at 6 sites Phase 1/2 Cancer Research UK · Birmingham and 6 other locations · NCT06045910

• Training for oncologists to improve communication with lymphoma patients

  This study tests a new training program for oncologists to help them communicate better with patients who have diffuse large B-cell lymphoma about their diagnosis and care options.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York and 1 other locations · NCT05940272

• Using Tagraxofusp to treat pediatric patients with relapsed or refractory blood cancers

  This study is testing a new drug called Tagraxofusp to see if it can help children and young adults with tough-to-treat blood cancers feel better and improve their chances of recovery.

  Recruiting at 15 sites Phase 1 Therapeutic Advances in Childhood Leukemia Consortium · Los Angeles, California and 30 other locations · NCT05476770

• Testing STP938 for patients with relapsed or refractory B-Cell and T-Cell lymphomas

  This study is testing a new drug called STP938 to see if it can help adults with tough-to-treat B-cell and T-cell lymphomas feel better.

  Recruiting at 15 sites Phase 1/2 Step Pharma, SAS · Denver, Colorado and 14 other locations · NCT05463263

• Evaluating Keynatinib for relapsed B-cell lymphoma

  This study is testing a new drug called Keynatinib to see if it can help people with relapsed B-cell lymphoma feel better and improve their treatment outcomes.

  Recruiting at 3 sites Phase 1 Medolution Ltd. · Beijing, Beijing Municipality and 3 other locations · NCT04807881

• CAR-T therapy outcomes and quality of life in older adults with B‑cell lymphoma

  This project will see how CAR‑T therapy affects older adults (age 60+) with relapsed or refractory B‑cell lymphomas, focusing on daily function and quality of life while they receive standard care.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York · NCT04300998

• Study of family connections in blood and lymph cancers

  This study looks at families with multiple members diagnosed with blood and lymph cancers to see if genetics and environmental factors play a role in their development.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT00626496

Related topics

Quick answers

How many Lymphoma, B-Cell clinical trials are recruiting right now?

19, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 8 countries. The most sites are in United States (11 trials), Australia (3 trials), China (3 trials), France (2 trials), United Kingdom (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 4, Phase 1/2: 3, Phase 3: 1, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →